Poster Pearl: A 2-Biomarker Class MCED Test Delivers High Specificity and Sensitivity
Host: Brian P. McDonough, MD, FAAFP Guest: Frank Diehl, PhD A poster presented at the 2024 American Association for Cancer Research Annual Meeting showcased findings from the ASCEND 2 study, which examined the performance of a multi-cancer early detection (MCED) test design that included methylation and protein biomarkers. The study found that this test design achieved overall sensitivity of 50.9 percent for all cancers at a high specificity of 98.5 percent. Dive further into these results and what they might mean for early cancer detection with Dr. Brian McDonough and Dr. Frank Diehl, Senior Vice President of Multi Cancer Early Detection at Exact Sciences Corporation.